Brought to you by 
Abgenix and U3 develop anticancer therapeutic antibodies
22 Jul 2002
Executive Summary
Abgenix (human antibody development) and U3 Pharma AG (cellular signal transduction) entered an agreement to discover and develop antibody therapeutics aimed at UB's cancer targets. Abgenix will use its XenoMouse and/or XenoMax technologies to generate the antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abgenix and U3 develop anticancer therapeutic antibodies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice